| Assessment Status | Rapid Review Complete |
| HTA ID | 26033a |
| Drug | Darolutamide |
| Brand | Nubeqa® |
| Indication | Darolutamide (Nubeqa®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). |
| Assessment Process | |
| Rapid review commissioned | 08/07/2026 |
| Rapid review completed | 04/08/2026 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that darolutamide plus ADT not be considered for reimbursement at the submitted price*. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here